Mpox Cases Remain Lower in 2026, But Vigilance Remains Key
The global health community continues to monitor mpox, formerly known as monkeypox, as cases remain significantly lower in 2026 compared to the outbreak experienced in 2022 and 2025. Whereas the virus hasn’t disappeared, proactive surveillance and public health measures appear to be containing its spread. As of February 2026, Brazil has reported 90 confirmed and probable cases, a marked decrease from the 1,079 cases recorded across the entire year of 2025. This decline, however, doesn’t diminish the need for continued awareness and preventative strategies, particularly among at-risk populations. Understanding the symptoms, transmission routes, and available resources remains crucial in mitigating further outbreaks of this viral infection.
Mpox is a viral infection primarily spread through direct contact with skin lesions, bodily fluids, or contaminated materials. The initial symptoms of mpox can often be mistaken for other viral illnesses, making early diagnosis challenging. According to the Brazilian Society of Infectious Diseases, early signs typically include fever, body aches, headache, chills, fatigue, and sore throat. A key indicator is often the swelling of lymph nodes (adenomegalia), a common clinical finding. These initial symptoms can make it challenging to distinguish mpox from other more common viral infections, highlighting the importance of considering mpox in the differential diagnosis, especially for individuals who may have been exposed.
Recognizing the Symptoms of Mpox
The hallmark of mpox is the development of skin lesions. These typically appear one to three days after the onset of fever, though they can sometimes precede it. The lesions progress through distinct stages, beginning as flat or slightly raised spots, evolving into fluid-filled blisters (vesicles) containing clear or yellowish liquid, and ultimately forming crusts that eventually dry and fall off. The number of lesions can vary widely, ranging from a few to thousands, and they commonly appear on the face, palms of the hands, soles of the feet, and can likewise affect the mouth, eyes, and genital areas.
Transmission of the mpox virus occurs primarily through skin-to-skin contact, particularly during sexual contact. The incubation period, the time between exposure and symptom onset, ranges from three to 16 days, with a possible extension to 21 days, according to Brazil’s Ministry of Health. Data from official sources indicate that in 2026, approximately 60% of reported cases have been linked to sexual contact between men, 7% between women, and 7% between men and women. The World Health Organization also emphasizes that the virus can be transmitted through contact with contaminated materials, infected animals, and, to a lesser extent, through respiratory droplets in close-quarters environments, especially during the early stages of symptoms. An individual is no longer considered contagious once all crusts have fallen off.
Brazil’s Mpox Situation in 2026: A Regional Breakdown
As of early February 2026, Brazil has recorded 90 cases of mpox – 88 confirmed and two probable – with no fatalities reported. The majority of cases have presented as mild to moderate. São Paulo state currently leads the country with 63 cases, followed by Rio de Janeiro (15), Rondônia (4), Minas Gerais (3), Rio Grande do Sul (2), and single cases reported in Santa Catarina, Paraná, and the Federal District. Over 180 additional cases are currently under investigation, with 57 already ruled out. This regional distribution underscores the importance of targeted public health interventions and awareness campaigns in areas with higher case concentrations.
Comparing 2026 Numbers to the 2025 Outbreak
While the current number of cases warrants attention, the situation is considerably more controlled than it was in 2025. Brazil concluded 2025 with a total of 1,079 mpox cases and two deaths. Examining the data from the first eight weeks of each year reveals a significant difference. By February 20, 2025, the country had already recorded 244 cases. In contrast, the total for the same period in 2026 is substantially lower. At the end of February 2025, there were 31 registered cases during the corresponding week, compared to just two cases this year. This substantial decrease suggests the effectiveness of ongoing vaccination efforts and public health messaging.
The Brazilian Ministry of Health maintains active surveillance, monitoring cases on a weekly epidemiological basis and ensuring the Unified Health System (SUS) is prepared for early diagnosis, clinical management, and patient follow-up. This proactive approach is critical for preventing larger outbreaks and protecting vulnerable populations. The Ministry of Health has not yet released specific data on vaccination rates, but continues to emphasize the importance of vaccination for those at higher risk of exposure.
The decline in cases is also attributed to increased awareness and behavioral changes within at-risk communities. Public health campaigns have focused on promoting safe sexual practices, encouraging early detection of symptoms, and providing access to testing and vaccination. These efforts, combined with the natural immunity developed by those previously infected, have contributed to the current downward trend.
Understanding Mpox Transmission and Risk Factors
Mpox is a zoonotic virus, meaning it originates in animals and occasionally transmits to humans. The primary reservoirs of the virus are non-human primates, such as little monkeys and rodents. Transmission to humans typically occurs in regions near African villages where contact with these animals is more frequent, either through proximity or consumption. This close contact allows the virus to jump from animals to humans, initiating the cycle of human-to-human transmission.
While anyone can contract mpox, certain populations are at higher risk. Men who have sex with men represent a disproportionately large percentage of cases, highlighting the importance of targeted prevention efforts within this community. Individuals with weakened immune systems, such as those living with HIV, are also more susceptible to severe illness and complications. The virus can cause pneumonia and brain infections in immunocompromised individuals, increasing the risk of mortality.
The availability of a vaccine against mpox, even prior to the 2022 outbreak, is a crucial tool in preventing infection and mitigating the severity of illness. However, access to the vaccine remains a challenge in many parts of the world, particularly in low- and middle-income countries. Efforts to increase vaccine production and distribution are essential to ensure equitable access for all who need it.
In individuals with healthy immune systems, mpox typically presents as a benign and self-limiting illness, lasting seven to 28 days. However, those with compromised immune systems face a higher risk of severe complications. Early diagnosis and appropriate medical care are crucial for managing the illness and preventing long-term health consequences.
The ongoing monitoring of mpox cases and the implementation of effective public health strategies are essential to prevent future outbreaks and protect global health security. Continued research into the virus, its transmission patterns, and the effectiveness of vaccines and treatments will be vital in controlling this evolving threat.
The Brazilian Ministry of Health will continue to provide updates on the mpox situation through its official channels. For more information, please visit the Ministry of Health website: https://www.gov.br/saude/pt-br. The World Health Organization also provides comprehensive information on mpox: https://www.who.int/news-room/q-a-detail/monkeypox.
What are your thoughts on the current mpox situation? Share your comments below, and facilitate us spread awareness about this crucial public health issue.